Anthem Biosciences peers

·Pharma & HealthChart ›

Companies like Anthem Bioscienceslatest year

Anthem BiosciencesANTHEM · FY26 · this company
Market cap₹46,631
P/E78.69×
Sales growth−22.6%
ROE19.5%
Syngene InternationalSYNGENE · FY26
Open ›
Market cap₹16,060
P/E50.65×
Sales growth−8.6%
ROE6.6%
Divi's LaboratoriesDIVISLAB · FY26
Open ›
Market cap₹2,56,096
P/E99.89×
Sales growth+27.8%
ROE16.2%
Glaxosmithkline PharmaceuticalsGLAXO · FY26
Open ›
Market cap₹42,608
P/E46.13×
Sales growth+16.6%
ROE49.1%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ANTHEM₹830.15

Anthem Biosciences Ltd.

· Pharma & Health
₹ CrorePeersSYNGENEDIVISLABGLAXOAJANTPHARMIPCALABABBOTINDIAMEDANTAGLENMARKMcap ₹46,631 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
ANTHEM
FY26
SYNGENE
FY26
DIVISLAB
FY26
GLAXO
FY26
Peer
Average
Valuation — at last close
P/E78.69×50.65×99.89×◆ 46.13×65.56× +20%
P/B15.33×◆ 3.32×15.28×18.79×12.46× +23%
EV/EBITDA54.86×◆ 16.09×73.43×30.43×39.99× +37%
Market Cap₹46,631 Cr₹16,060 Cr₹2.56L Cr₹42,608 Cr₹1.05L Cr -56%
Growth
Revenue CAGR 3Y—5.40%◆ 10.78%5.53%7.24%
Revenue CAGR 5Y—◆ 11.35%8.67%3.62%7.88%
Net Income CAGR 3Y—-11.98%12.09%◆ 19.26%6.46%
Revenue YoY (latest Q)-22.58%-8.55%◆ 27.80%16.55%11.93% -289%
Net Income YoY (latest Q)-11.67%-52.01%◆ 65.50%15.69%9.73% -220%
Profitability
EBITDA Margin◆ 39.25%24.57%32.59%34.26%30.47% +29%
Net Income Margin◆ 27.86%8.47%24.32%27.11%19.97% +40%
Return on Common Equity19.45%6.62%16.19%◆ 49.11%23.97% -19%
Return on Capital Employed22.55%8.54%17.80%◆ 52.35%26.23% -14%
Return on Assets17.26%4.57%13.89%◆ 24.57%14.34% +20%
Credit & Quality
Total Debt/Equity0.02×◆ 0.00×0.00×0.00×0.00×
Interest Coverage101.50×9.54×129.48×◆ 455.22×198.08× -49%
Scale — latest FY
Revenue / Total Income₹2,124 Cr₹3,739 Cr₹10,560 Cr₹3,822 Cr₹6,040 Cr -65%
Net Income₹592 Cr₹317 Cr₹2,568 Cr₹1,036 Cr₹1,307 Cr -55%
Total Assets₹3,429 Cr₹7,055 Cr₹20,033 Cr₹4,324 Cr₹10,471 Cr -67%
EPS₹10.55₹7.87₹96.75₹54.52₹53.05 -80%
Book Value per Share₹54.16₹120.11₹632.49₹133.84₹295.48 -82%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.